NeuroPace (NPCE) Cash & Equivalents (2020 - 2026)

NeuroPace has reported Cash & Equivalents for 7 years, with the latest figure at $12.5 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 45.15% year-over-year to $12.5 million in Q2 2026; TTM through Jun 2026 was $12.5 million, a 45.15% decrease from a year earlier, with the FY2025 full-year figure at $21.7 million, up 61.52% from the prior year.
• Cash & Equivalents was $12.5 million for Q2 2026 at NeuroPace, down from $14.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $27.0 million in Q1 2025, with the low at $5.7 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $13.4 million, with a median of $12.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 81.75% in 2022, then soared 173.4% in 2023.
• Over 5 years, Cash & Equivalents stood at $6.6 million in 2022, then jumped by 173.4% to $18.1 million in 2023, then decreased by 25.63% to $13.4 million in 2024, then jumped by 61.52% to $21.7 million in 2025, then plunged by 42.2% to $12.5 million in 2026.
• The last three Cash & Equivalents figures came in at $12.5 million (Q2 2026), $14.8 million (Q1 2026), and $21.7 million (Q4 2025), per Business Quant data.